[APRI] Apricus Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.32 Change: 0.13 (10.92%)
Ext. hours: Change: 0 (0%)

chart APRI

Refresh chart

Strongest Trends Summary For APRI

APRI is in the medium-term down -32% in 5 months. In the long-term down -96% below S&P in 12 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Apricus Biosciences, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for men?s and women?s health. The company?s lead product, Vitaros, has approved for the treatment of erectile dysfunction in Canada and Europe. It is also developing Vitaros product candidate (room temperature Vitaros) that is a proprietary stabilized dosage formulation, which can be stored at room temperature conditions. The company?s product candidate in the areas of women?s health includes Femprox, an alprostadil-based cream product candidate intended for the treatment of female sexual interest/arousal disorder that has completed an approximately 400-subject proof-of-concept study. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

Fundamental Ratios
Shares Outstanding EPS-1.16 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -91.29% Sales Growth - Q/Q-75.09% P/E-0.93
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-126.99% ROE-1493.17% ROI
Current Ratio2.52 Quick Ratio2.49 Long Term Debt/Equity Debt Ratio4.29
Gross Margin88.18% Operating Margin-258.25% Net Profit Margin-256.17% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities11.05 M Cash From Investing Activities-170 K Cash From Operating Activities-6.13 M Gross Profit240 K
Net Profit-6.41 M Operating Profit-6.12 M Total Assets19.64 M Total Current Assets18.04 M
Total Current Liabilities7.16 M Total Debt4.83 M Total Liabilities17.97 M Total Revenue470 K
Technical Data
High 52 week4.38 Low 52 week0.26 Last close2.72 Last change-1.81%
RSI30.67 Average true range0.15 Beta0.25 Volume153.23 K
Simple moving average 20 days-6.58% Simple moving average 50 days-8.74% Simple moving average 200 days116.64%
Performance Data
Performance Week-4.9% Performance Month-11.11% Performance Quart-25.89% Performance Half504.44%
Performance Year55.43% Performance Year-to-date871.43% Volatility daily3.41% Volatility weekly7.62%
Volatility monthly15.62% Volatility yearly54.12% Relative Volume70.45% Average Volume4.93 M
New High New Low

News

2019-03-29 14:43:45 | Why Seelos Therapeutics Shares Are Surging Out Of The Gate

2019-01-24 08:01:00 | Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System CNS Disorders

2019-01-15 07:00:00 | Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc.

2018-12-14 12:30:00 | Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date

2018-12-10 07:00:00 | Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018

2018-11-16 08:30:00 | Report: Exploring Fundamental Drivers Behind Zedge, Apricus Biosciences, AquaBounty Technologies, Clarus, Dynasil Corporation of America, and The Rubicon Project — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-31 16:30:48 | Apricus: 3Q Earnings Snapshot

2018-10-31 16:24:49 | Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results

2018-08-09 18:18:39 | Apricus: 2Q Earnings Snapshot

2018-08-09 16:05:00 | Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results

2018-07-30 08:00:00 | Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System CNS Disorders

2018-07-02 07:05:00 | Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

2018-06-04 14:02:20 | What Does Apricus Biosciences Inc’s NASDAQ:APRI Share Price Indicate?

2018-06-04 07:30:00 | Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks

2018-05-24 17:23:20 | With A -24.18% Earnings Drop, Is Apricus Biosciences Inc’s NASDAQ:APRI A Concern?

2018-05-03 17:40:41 | Apricus: 1Q Earnings Snapshot

2018-05-03 16:02:01 | Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:

2018-04-16 08:41:56 | Benzinga Pro's 5 Stocks To Watch Today

2018-04-16 08:25:54 | Apricus mulls options; to sell U.S. rights to Vitaros

2018-04-16 07:06:47 | FDA asks for new formulation of Apricus' erectile dysfunction cream

2018-04-16 07:01:00 | Apricus Biosciences Announces Outcome of VitarosTM End-of-Review Meeting with FDA

2018-04-16 07:00:00 | Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA

2018-04-04 16:01:00 | Apricus Biosciences Announces Closing of $3.55 Million Public Offering

2018-03-29 06:31:39 | Edge Therapeutics And Apricus Biosciences Are Moving: Here’s Why

2018-03-28 08:01:01 | Apricus Biosciences Announces Pricing of $3.55 Million Public Offering

2018-03-27 16:40:04 | Apricus Biosciences Announces Proposed Public Offering

2018-03-26 15:26:01 | Apricus Biosciences Announces Scheduling of VitarosTM End-of-Review Meeting with FDA

2018-03-26 07:00:00 | Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA

2018-03-22 08:05:00 | Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline

2018-03-22 07:30:00 | Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash

2018-03-06 08:01:22 | Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT

2018-03-01 17:09:16 | Apricus reports 4Q loss

2018-03-01 16:02:01 | Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results

2018-03-01 16:01:00 | Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results

2018-03-01 12:00:00 | Apricus Biosciences, Inc. to Host Earnings Call

2018-03-01 11:15:19 | At $0.9401, Is Apricus Biosciences Inc NASDAQ:APRI A Buy?

2018-02-28 10:08:00 | Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

2018-02-21 08:50:01 | Apricus Biosciences APRI Soars: Stock Adds 8.6% in Session

2018-02-21 07:01:00 | Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call

2018-02-20 10:41:02 | Here’s What’s Moving Apricus Biosciences And Pacira Pharmaceuticals

2018-02-20 09:39:50 | What's Next For Apricus Biosciences' Vitaros?

2018-02-19 02:00:50 | Interested In Apricus Biosciences Inc NASDAQ:APRI? Here’s What Its Recent Performance Looks Like

2018-02-16 12:20:16 | Is It “Game Over” After Apricus Biosciences Inc APRI FDA Rejection?

2018-02-16 11:23:39 | There's No Place Like Home in Biotech

2018-02-16 08:59:11 | Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

2018-02-16 08:52:09 | Benzinga Pro's 5 Stocks To Watch Today

2018-02-16 07:07:47 | U.S. FDA declines to approve Apricus' erectile dysfunction cream

2018-02-16 07:01:01 | Apricus Biosciences Receives Complete Response Letter from FDA for VitarosTM

2018-02-16 07:00:00 | Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™

2017-11-21 13:39:09 | Should You Buy Apricus Biosciences Inc APRI Now?